Jobs
-
Renovion has initiated a Phase 3 clinical study of its ARINA-1 inhaled glutathione / bicarbonate / ascorbic acid for the treatment of bronchiolitis obliterans syndrome (BOS) following bilateral lung transplant. ARINA-1 recently received Fast Track… Read more . . .
-
ReCode Therapeutics, which is developing inhaled mRNA therapeutics for the treatment of primary ciliary dyskinesia and cystic fibrosis, has named John G. Matthews as Senior VP of Clinical Development. ReCode initiated a Phase 1 trial… Read more . . .
-
Satsuma Pharmaceuticals, which was spun out of Shin Nippon Biomedical Laboratories (SNBL) over 6 years ago to develop an intranasal dry powder formulation of dihydroergotamine, has announced that it will now be acquired by SNBL.… Read more . . .
-
Tonix Pharmaceuticals said that it will reduce enrollment in the recently initiated Phase 2 PREVENTION study of TNX-1900 intranasal potentiated oxytocin in migraine patients from about 300 subjects to about 150 subjects, with a goal… Read more . . .
-
University of California, San Francisco spinout Aer Therapeutics has closed a $36 million Series A financing, with funds intended to support development of the company’s AER-01 inhaled mucolytic for the treatment of COPD, the company… Read more . . .
-
US-based startup Pocket Naloxone said that a human factors study of its NaxSwab OTC naloxone nasal swab demonstrated that the swab could be used effectively in a simulated emergency by a wide range of people,… Read more . . .
-
Tiziana Life Sciences has announced that the company will develop intranasal foralumab for the treatment of long COVID. In August 2021, Tiziana announced positive results from a pilot study of intranasal foralumab in mild-to-moderate COVID.… Read more . . .
-
HCmed Innovations announced that former AstraZeneca Science and Innovation Director of Inhaled Drug Delivery Gunilla Petersson has joined the company as Chief Scientific Officer. Petersson has almost 30 years of experience in the pharmaceutical industry, primarily… Read more . . .
-
According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent that will protect the company’s Gimoti metaclopramide nasal spray until 2030. The patent (No.… Read more . . .
-
Nuance Pharma has initiated the ENHANCE – China Phase 3 study of nebulized ensifentrine in mainland China, the company said. Nuance obtained the rights to develop and market ensifentrine in China, Macau, Taiwan, and Hong Kong… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan